Annals of Oncology Advance Access originally published online on November 23, 2007
Annals of Oncology 2008 19(4):675-681; doi:10.1093/annonc/mdm538
breast cancer |
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes
1 Department of Surgery
2 Department of Biochemistry & Molecular Biology
3 Department of Internal Medicine
4 Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea
* Correspondence to: Prof. B.-W. Park, Department of Surgery, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-ku, Seoul 120-752, South Korea. Tel: +82-2-2228-2121; Fax: +82-2-313-8289; E-mail: bwpark{at}yumc.yonsei.ac.kr
Background: To investigate the association between tumor markers [cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)] and clinicopathological parameters and patient outcomes in breast cancer.
Materials and methods: A total of 740 patients with stages I–III breast cancer had preoperative CA 15-3 and CEA concentrations measured. Univariate and multivariate analyses were used to investigate associations between marker concentration and clinicopathological parameters and patient outcomes.
Results: Among 740 patients, elevated preoperative levels of CA 15-3 and CEA were identified in 92 (12.4%) and 79 (10.7%) patients, respectively. Tumor size (>5 cm), node metastases (
4), and advanced stage (III) were associated with higher preoperative levels. Elevated CA 15-3 and CEA levels were associated with poor disease-free survival (DFS, P = 0.0014, P = 0.0001, respectively) and overall survival (OS, P = 0.018, P = 0.015) even in stage-matched analysis. Patients with normal levels of both CA 15-3 and CEA showed better DFS and OS than those with elevated group. In multivariate analysis, age (<35 years), tumor size (>2 cm), node metastases, estrogen receptor expression, and elevated CA 15-3 and CEA preoperative values were independent prognostic factors for DFS.
Conclusion: High preoperative CA 15-3 and CEA levels may reflect tumor burden and are associated with advanced disease and poor outcome. Measuring preoperative levels of CA 15-3 and CEA can be helpful for predicting outcomes.
Key words: breast cancer, CA 15-3, CEA, prognosis, tumor marker
Received for publication August 24, 2006. Revision received October 4, 2007. Accepted for publication October 22, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Park, J. Koo, H. S. Park, J.-H. Kim, S.-Y. Choi, J. H. Lee, B.-W. Park, and K. S. Lee Expression of androgen receptors in primary breast cancer Ann. Onc., November 3, 2009; (2009) mdp510v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Desmetz, C. Bascoul-Mollevi, P. Rochaix, P.-J. Lamy, A. Kramar, P. Rouanet, T. Maudelonde, A. Mange, and J. Solassol Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women Clin. Cancer Res., July 15, 2009; 15(14): 4733 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chourin, D. Georgescu, C. Gray, C. Guillemet, A. Loeb, C. Veyret, and J.-P. Basuyau Value of CA 15-3 determination in the initial management of breast cancer patients Ann. Onc., May 1, 2009; 20(5): 962 - 964. [Full Text] [PDF]
|
|